Recently, according to an official article from Marketingforce, Mifushi has officially signed a strategic cooperation agreement with Shandong Focus Freda Biotechnology Co., Ltd. (hereinafter referred to as Focus Freda) for 2025.
The article highlights that in vertical industries such as medical aesthetics and medical devices, sodium hyaluronate (hyaluronic acid) is a key ingredient. With the rapid development of the biopharmaceutical industry, its application fields have been expanding, and market demand has been continuously rising. Focus Freda, with its leading hyaluronic acid production technology, has seen its products exported to more than 70 countries and regions, securing an important position in the industry. However, faced with a rapidly changing market environment, diverse customer groups, and fragmented marketing channels, Focus Freda urgently needs to enhance its brand competitiveness and cultivate loyal customers through digital transformation and intelligent upgrades.
In this context, both parties will focus on deep cooperation in areas such as customer data management, marketing strategy development, and operational channel integration. Leveraging AI Agent technology, they will jointly build an integrated digital and intelligent marketing platform that targets both B2B and B2C markets. This platform will help Focus Freda’s existing marketing system transform from digitalization to intelligence, enhancing business collaboration and overall operational capabilities.
According to the National Enterprise Credit Information Publicity System, Focus Freda was founded in 2012 with a registered capital of 17.97 million yuan ($136,800). Its main business scope includes the development, production, and sale of hyaluronic acid, sodium hyaluronate and its derivatives, sodium glass acid, active pharmaceutical ingredients, pharmaceutical excipients, and other products. The largest shareholder of Focus Freda is Lushang Freda Pharmaceutical Co., Ltd. (Freda, 600223.SH), which holds 60% of its shares.
Freda, established in 1993, is a leader in hyaluronic acid research and application technology in the biopharmaceutical sector. It operates under the Shandong Freda Pharmaceutical Group and is involved in industries such as active pharmaceutical ingredients, medicines, medical devices, health food, food, and cosmetics. Freda has seven production bases for biological fermentation raw materials, plant extraction raw materials, chemical synthesis active pharmaceutical ingredients, drug formulations, skincare and fragrance cosmetics in Jinan, Linyi, and Yining, Xinjiang.
According to the financial report, in the first three quarters of 2024, Freda achieved a revenue of 2.803 billion yuan ($383.6 million), a year-on-year decrease of 17.45%. The net profit attributable to the shareholders of the listed company was 171 million yuan ($23.4 million), a year-on-year decrease of 28.09%. Among these, the cosmetics business achieved a revenue of 1.708 billion yuan ($233.7 million), a year-on-year increase of 3.25%. Specifically, the company’s brands, Yilian and Aierbo, both achieved good sales results, with revenues of 658 million yuan ($90 million) and 909 million yuan ($124.4 million), a year-on-year increase of 7.57% and 1.80%, respectively.
